Trepipam

Trepipam (INN) is a dopamine receptor agonist of the benzazepine group that was never marketed.[1] It acts specifically as an agonist of the dopamine D1 receptor.[2] It is closed related structurally to fenoldopam, a peripherally acting selective D1 receptor partial agonist which is used as an antihypertensive agent.

Trepipam
Identifiers
IUPAC name
  • 7,8-Dimethoxy-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC19H23NO2
Molar mass297.398 g·mol−1
3D model (JSmol)
SMILES
  • CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)OC)OC
InChI
  • InChI=1S/C19H23NO2/c1-20-10-9-15-11-18(21-2)19(22-3)12-16(15)17(13-20)14-7-5-4-6-8-14/h4-8,11-12,17H,9-10,13H2,1-3H3
  • Key:ICPHJSKVAZMKIV-UHFFFAOYSA-N

References
  1. Lednicer D (4 March 2009). Strategies for Organic Drug Synthesis and Design. John Wiley & Sons. pp. 495–. ISBN 978-0-470-39959-0.
  2. Goode-Romero G, Winnberg U, Domínguez L, Ibarra IA, Vargas R, Winnberg E, Martínez A (December 2020). "New information of dopaminergic agents based on quantum chemistry calculations". Sci Rep. 10 (1): 21581. Bibcode:2020NatSR..1021581G. doi:10.1038/s41598-020-78446-4. PMC 7725812. PMID 33299000.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.